Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

112
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
112
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

146
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
146
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

39
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
39
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

294
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
294
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

177
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
177
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma.

Journal of chromatographic science·2026
Same author

Preclinical Development of GT-14, a Novel Inhibitor of Gα<sub>i</sub>2 Protein: Comprehensive Evaluation of Physicochemical, Metabolic Characteristics and Tissue Distribution.

The AAPS journal·2025
Same author

Development and validation of a novel LC-MS/MS method for simultaneous quantification of alvocidib and its glucuronide: application to pharmacokinetic and tissue distribution study in rats.

Analytical methods : advancing methods and applications·2025
Same author

Drug Metabolism and Pharmacokinetic Evaluation of a Novel RNase H2 Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Pharmaceutics·2025
Same author

Clay Attenuates Diarrhea Induced by Fat in a Mouse Model.

Metabolites·2025
Same author

An LC-MS Method to Quantify Rhein and Its Metabolites in Plasma: Application to a Pharmacokinetic Study in Rats.

Metabolites·2025
Same journal

Lactate Metabolism Dysregulation Drives the Pathogenesis of Acute Kidney Injury.

Metabolites·2026
Same journal

Librarian: An Open-Access Web Application for High-Resolution Mass Spectral Library Assembly.

Metabolites·2026
Same journal

Purine Metabolism Alterations in Patients with Chronic Heart Failure: A Cross-Sectional Study of Associations with Iron Status, Oxidative Stress, and Anemia.

Metabolites·2026
Same journal

The Gut Microbiome in Heart Failure: Pathways to Inflammation and Therapeutic Targets.

Metabolites·2026
Same journal

Metabolic Mechanisms of Hexavalent Chromium-Induced Splenic Immune Injury via Oxidative Stress and Ferroptosis Pathways in New Zealand Rabbits.

Metabolites·2026
Same journal

Improving Speed and Efficiency of DESI Imaging with the Xevo MRT Mass Spectrometer for Analyte Mapping.

Metabolites·2026
查看所有相关文章

相关实验视频

Updated: Jun 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

在Ezetimibe糖化中的物种差异.

Shalom Emmanuel1, Eric A Asare1, Ting Du1

  • 1Department of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.

Metabolites
|November 26, 2024
PubMed
概括
此摘要是机器生成的。

观察到ezetimibe糖化率的物种差异,影响其新陈代谢. 这些变异对于在不同模型中对ezetimibe进行准确的药理动力学和毒理学评估至关重要.

关键词:
美国UGT公司埃塞蒂米贝贝是什么意思葡萄糖化剂的使用方法种类的差异 种类的差异 种类的差异

更多相关视频

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
13:35

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

191

相关实验视频

Last Updated: Jun 6, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K
Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota
13:35

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

191

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 药物新陈代谢 药物新陈代谢
  • 生物化学 生化学

背景情况:

  • 作为胆固醇吸收抑制剂的埃泽蒂米布被广泛代谢成埃泽蒂米布葡萄糖化物.
  • 代谢中的物种差异对于准确的药理动力学和药理动力学评估至关重要.
  • 了解ezetimibe糖化变异性对于药物开发和安全性评估至关重要.

研究的目的:

  • 为了比较ezetimibe糖化率的物种差异.
  • 用人类,老鼠,小鼠,子和狗的肠道显微体来研究ezetimibe的葡萄化.

主要方法:

  • 使用了来自多个物种的肠道显微体.
  • 在各种基质度 (0.550μM) 中评估了埃泽提的葡萄化率.
  • 用迈凯利斯-门模型确定了酶动态参数.

主要成果:

  • 在物种之间发现了埃泽胺基葡萄化率的显著差异.
  • 子肠道显微体表现出最高的Vmax,其次是老鼠,小鼠,人类和狗.
  • 在物种内清除 (CLint) 显示了8.17倍的变化,老鼠>狗>人类>老鼠=子.

结论:

  • 肠道埃泽胺基糖化率的特定物种差异显著影响药物代谢.
  • 在分析ezetimibe的药理动力学,药理动力学和毒理学时,必须考虑这些变化.
  • 准确地解释ezetimibe研究需要考虑物种间的代谢差异.